Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo‐controlled double‐blind randomized clinical trial with cannabidiol
Journal of Periodontal Research · 2024
DOI: 10.1111/jre.13234 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Periodontal Research, 2024. Verfasst von Petr Jirasek und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Dentistry and Oral Sciences, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. Hauptthemen laut MEDLINE: Cannabidiol, Fibroblasts, Gingiva, Gingivitis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: UPOL, ENOCH.
Abstract (Originalsprache)
Objective
The aim of this study was to: (1) evaluate the anti‐inflammatory effects of cannabidiol (CBD) on primary cultures of human gingival fibroblasts (HGFs) and (2) to clinically monitor the effect of CBD in subjects with periodontitis.
Background
The use of phytocannabinoids is a new approach in the treatment of widely prevalent periodontal disease. Materials and Methods Cannabinoid receptors were analyzed by western blot and interleukin production detected using enzyme immunoassay. Activation of the Nrf2 pathway was studied via monitoring the mRNA level of heme oxygenase‐1. Antimicrobial effects were determined by standard microdilution and 16S rRNA screening. In the clinical part, a placebo‐control double‐blind randomized study was conducted (56 days) in three groups ( n = 90) using dental gel without CBD (group A) and with 1% ( w/w ) CBD (group B) and corresponding toothpaste (group A – no CBD, group B – with CBD) for home use to maintain oral health. Group C used dental gel containing 1% chlorhexidine digluconate (active comparator) and toothpaste without CBD.
Results
Human gingival fibroblasts were confirmed to express the cannabinoid receptor CB2. Lipopolysaccharide‐induced cells exhibited increased production of pro‐inflammatory IL‐6 and IL‐8, with deceasing levels upon exposure to CBD. CBD also exhibited antimicrobial activities against Porphyromonas gingivalis , with an MIC of 1.5 μg/mL. Activation of the Nrf2 pathway was also demonstrated. In the clinical part, statistically significant improvement was found for the gingival, gingival bleeding, and modified gingival indices between placebo group A and CBD group B after 56 days.
Conclusions
Cannabidiol reduced inflammation and the growth of selected periodontal pathogenic bacteria. The clinical trial demonstrated a statistically significant improvement after CBD application. No adverse effects of CBD were reported by patients or observed upon clinical examination during the study. The results are a promising basis for a more comprehensive investigation of the application of non‐psychotropic cannabinoids in dentistry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Dentistry and Oral Sciences, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- Institute of Dentistry and Oral Sciences, University Hospital Olomouc, Olomouc, Czech Republic.
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- Department of Clinical and Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- Department of Microbiology, Faculty of Medicine of Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.
- Department of Analytical Chemistry, Faculty of Science, Palacky University, Olomouc, Czech Republic.
ORCID-Profile: Petr Jirasek, Jan Vacek
Förderung
- UPOL
- ENOCH
Zitieren
APA
Jirasek, P., Jusku, A., Frankova, J., Urbankova, M., Diabelko, D., Ruzicka, F., Papouskova, B., Chytilova, K., Vrba, J., Havlasek, J., Langova, K., Storch, J., Voborna, I., Simanek, V., & Vacek, J. (2024). Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo‐controlled double‐blind randomized clinical trial with cannabidiol. Journal of Periodontal Research. https://doi.org/10.1111/jre.13234
Vancouver
Jirasek P, Jusku A, Frankova J, Urbankova M, Diabelko D, Ruzicka F, et al. Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo‐controlled double‐blind randomized clinical trial with cannabidiol. Journal of Periodontal Research. 2024. doi:10.1111/jre.13234
BibTeX
@article{Jirasek2024,
author = {Jirasek, Petr and Jusku, Alexandr and Frankova, Jana and Urbankova, Marketa and Diabelko, Daniel and Ruzicka, Filip and Papouskova, Barbora and Chytilova, Karin and Vrba, Jiri and Havlasek, Jakub and Langova, Katerina and Storch, Jan and Voborna, Iva and Simanek, Vilim and Vacek, Jan},
title = {Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo‐controlled double‐blind randomized clinical trial with cannabidiol},
journal = {Journal of Periodontal Research},
year = {2024},
doi = {10.1111/jre.13234}
}
EUVIMED